VizMark adds Chris L. Marsh to board as VM-1 rollout expands

VizMark Inc. appointed veteran executive Chris L. Marsh to its board of directors as the Minnesota medtech company scales distribution of VM-1, its FDA-cleared non-metallic breast biopsy marker. The move brings operating and dealmaking experience to a company moving from regulatory clearance toward broader clinical adoption.

Why it matters: - VizMark is pushing VM-1 from FDA clearance into commercial growth, and board-level experience in scaling, financing and exits can shape that transition. - The appointment adds a leader with experience across technology, medical technology and healthcare commercialization. - VizMark is the company behind VM-1, described as the first FDA-cleared non-metallic breast biopsy marker.

What happened: - VizMark Inc. appointed Chris L. Marsh to its Board of Directors on Sept. 30, 2026. - Marsh is CEO and co-founder of Facteus, Executive Chairman of Pacific Diabetic Technologies and Chairman of the Board of Point B. - Marsh joins VizMark as the company scales commercial distribution of VM-1. - VM-1 received FDA 510(k) clearance in December 2025.

The details: - Marsh has more than 30 years of experience as a chief executive, investor and board member. - His background spans technology, data and artificial intelligence, fintech, life sciences, medical technology and logistics. - Marsh has executed the grow-to-liquidity model 14 times across several industries. - Marsh has participated in more than 45 buy-side and sell-side transactions. - At Facteus, Marsh helped build an alternative-data and consumer transaction intelligence platform. - Facteus provides institutional investors, corporations and other organizations with insights derived from billions of consumer transactions and more than $4 trillion in annual consumer spending. - Under Marsh’s leadership, Facteus expanded from financial markets into corporate and advertising intelligence. - Facteus also built an AI-driven intelligence platform intended to turn proprietary transaction data into business insights. - At Pacific Diabetic Technologies, Marsh serves as Executive Chairman of a company developing an integrated insulin delivery and continuous glucose sensing platform. - Pacific Diabetic Technologies’ patented technology is designed to combine glucose sensing and insulin delivery through a single cannula. - The goal is to reduce the complexity and burden of diabetes management. - Marsh has helped guide strategy, financing, commercialization planning and strategic partnerships at Pacific Diabetic Technologies. - Earlier, Marsh served as president and CEO of Unicru, where he grew the talent-management software company from about 40 employees to 350. - Marsh led Unicru’s 2006 sale to Kronos for $170 million. - He was an investor and chairman at Auctionpay through its acquisition by Global Payments. - He served as CFO and COO of Card Capture Services through its sale to E*TRADE. - He was president and CEO of Superior Transportation Logistics through its sale to The Greenbrier Companies. - Marsh also served on the board of CloudMed Solutions through its 2018 sale to Revint. - Marsh holds a B.S. in business administration from Oregon State University. - He also completed executive education at the University of Michigan Ross School of Business. - VizMark CEO Kim Nelson said Marsh has repeatedly built differentiated technology businesses and the team, capital structure and commercial engine around them. - Nelson said Marsh’s operating discipline and transaction experience are important as VM-1 moves from clearance to broader clinical adoption. - Marsh said breast imaging has advanced, but the marker left behind at biopsy has not kept pace. - Marsh said VizMark has built a real solution to a real clinical problem with regulatory clearance and intellectual property to defend it.

Between the lines: - VizMark is signaling that commercialization, not just regulation, is the next hurdle for VM-1. - Marsh’s background suggests the company wants board support that goes beyond medtech expertise and into scaling, dealmaking and exits. - The appointment also ties VizMark to a director with experience in adjacent healthcare platforms, which could matter as the company seeks broader clinical adoption.

What's next: - VizMark is expected to keep expanding commercial distribution of VM-1. - The company’s next phase appears to center on adoption in clinical settings after FDA clearance. - Marsh is likely to play a role in strategy, commercialization and board oversight as VizMark scales.